Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zhi-An Zhu is active.

Publication


Featured researches published by Zhi-An Zhu.


Journal of Translational Medicine | 2012

Upregulation of SATB1 is associated with the development and progression of glioma

Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Zhi-An Zhu; Zhi-Qiang Li; Pu-Cha Jiang

BackgroundSpecial AT-rich sequence-binding protein-1 (SATB1) has been reported to be expressed in several human cancers and may have malignant potential. This study was aimed at investigating the expression and potential role of SATB1 in human glioma.MethodThe relationship between SATB1 expression, clinicopathological parameters, Ki67 expression and MGMT promoter methylation status was evaluated, and the prognostic value of SATB1 expression in patients with gliomas was analyzed. SATB1-specific shRNA sequences were synthesized, and U251 cells were transfected with SATB1 RNAi plasmids. Expression of SATB1 mRNA and protein was investigated by RT-PCR and immunofluoresence staining and western blotting. The expression of c-Met, SLC22A18, caspase-3 and bcl-2 protein was determined by western blotting. U251 cell growth and adherence was detected by methyl thiazole tetrazolium assay. The apoptosis of U251 cells was examined with a flow cytometer. The adherence, invasion, and in vitro angiogenesis assays of U251 cells were done. The growth and angiogenesis of SATB1 low expressing U251 cells was measured in an in vivo xenograft model.ResultsOf 70 tumors, 44 (62.9%) were positive for SATB1 expression. SATB1 expression was significantly associated with a high histological grade and with poor survival in univariate and multivariate analyses. SATB1 expression was also positively correlated with Ki67 expression but negatively with MGMT promoter methylation in glioma tissues. SATB1 shRNA expression vectors could efficiently induce the expression of SLC22A18 protein, increase the caspase-3 protein, inhibit the expression of SATB1, c-Met and bcl-2 protein, the growth, invasion, metastasis and angiogenesis of U251 cells, and induce apoptosis in vitro. Furthermore, the tumor growth of U251 cells expressing SATB1 shRNA were inhibited in vivo, and immunohistochemical analyses of tumor sections revealed a decreased vessel density in the animals where shRNA against SATB1 were expressed.ConclusionsSATB1 may have an important role as a positive regulator of glioma development and progression, and that SATB1 might be a useful molecular marker for predicting the prognosis of glioma.


Journal of Clinical Neuroscience | 2012

Correlation of low SLC22A18 expression with poor prognosis in patients with glioma.

Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Zhi-An Zhu; Zhi-Qiang Li; Pu-Cha Jiang

We investigated the expression of the putative tumor suppressor SLC22A18 to evaluate it as a prognostic marker in glioma patients. Immunohistochemical and Western blot analyses of clinical tissue samples obtained from 120 patients with glioma were performed. Low expression of SLC22A18 was observed in 71.7% of patients. Loss of SLC22A18 expression in glioma was significantly related to pathological grade (p = 0.003). High pathological grade (World Health Organization III-IV) was correlated with negative (low or absent) expression of SLC22A18, which was correlated with a significantly shorter overall patient survival than in those with positive (high) expression (p = 0.007). Multivariate Cox regression analysis indicated that SLC22A18 expression level is an independent survival prognostic factor for patients with glioma (p = 0.011). Western blotting analysis confirmed decreased expression of SLC22A18 in glioma tissues compared with adjacent brain tissues. This study suggests that SLC22A18 functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease.


Journal of Translational Medicine | 2011

Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma

Sheng-Hua Chu; Dong-Fu Feng; Yan-Bin Ma; Hong Zhang; Zhi-An Zhu; Zhi-Qiang Li; Pu-Cha Jiang

BackgroundDownregulation of the putative tumor suppressor gene SLC22A18 has been reported in a number of human cancers. The aim of this study was to investigate the relationship between SLC22A18 downregulation, promoter methylation and the development and progression of human glioma.MethodSLC22A18 expression and promoter methylation was examined in human gliomas and the adjacent normal tissues. U251 glioma cells stably overexpressing SLC22A18 were generated to investigate the effect of SLC22A18 on cell growth and adherence in vitro using the methyl thiazole tetrazolium assay. Apoptosis was quantified using flow cytometry and the growth of SLC22A18 overexpressing U251 cells was measured in an in viv o xenograft model.ResultsSLC22A18 protein expression is significantly decreased in human gliomas compared to the adjacent normal brain tissues. SLC22A18 protein expression is significantly lower in gliomas which recurred within six months after surgery than gliomas which did not recur within six months. SLC22A18 promoter methylation was detected in 50% of the gliomas, but not in the adjacent normal tissues of any patient. SLC22A18 expression was significantly decreased in gliomas with SLC22A18 promoter methylation, compared to gliomas without methylation. The SLC22A18 promoter is methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation. Stable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells.ConclusionSLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.


Journal of Neuro-oncology | 2009

c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro

Sheng-Hua Chu; Dong-Fu Feng; Hong Zhang; Er-Tao Chen; Zhi-Xin Duan; Xue-Yuan Li; Jia Li; Yan-Bin Ma; Zhi-An Zhu; Jian-Hua Qiu

Angiogenesis plays an essential role in tumor growth and metastasis and is a promising target for cancer therapy. c-Met, a receptor tyrosine kinase, and its ligand, hepatocyte growth factor (HGF), are critical in cellular proliferation, motility, invasion, and angiogenesis. The present study was designed to determine the role of c-Met in growth and metastasis of glioma U251 cells using RNA interference (RNAi) technology in vitro. We constructed three kinds of shRNA expression vectors aiming at the c-Met gene, then transfected them into glioma U251 cells by lipofectamineTM 2000. The level of c-Met mRNA was investigated by real-time polymerse chain reaction (RT-PCR). The protein expression of c-Met was observed by immunofluoresence staining and western blotting. U251 cell growth and adherence was detected by methyl thiazole tetrazolium assay. The apoptosis of U251 cells was examined with a flow cytometer. The adherence, invasion, and in vitro angiogenesis assays of U251 cells were done. We got three kinds of c-Met specific shRNA expression vectors which could efficiently inhibit the growth and metastasis of U251 cells and the expression of c-Met in U251 cells. RT-PCR, immunofluoresence staining and western blotting showed that inhibition rate for c-Met expression was up to 90%, 79% and 85%, respectively. The expression of c-Met can be inhibited by RNA interference in U251 cells, which can inhibit the growth and metastasis of U251 cell and induce cell apoptosis. These results indicate that RNAi of c-Met can be an effective antiangiogenic strategy for glioma.


Journal of Neuro-oncology | 2007

Erratum to: Hepatocyte growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells

Sheng-Hua Chu; Yan-Bin Ma; Hong Zhang; Dong-Fu Feng; Zhi-An Zhu; Zhiqiang Li; Xianhou Yuan

Hepatocyte growth factor (HGF) is a pleiotrophic cytokine that stimulates motility and invasion of several cancer cell types and induces angiogenesis, which is known to be expressed in several malignancies including glioma. The effect of transforming growth factor-beta (TGF-β) isoforrns as well as gangliosides on HGF production was investigated in human glioma cell lines. TGF-β isoforms and gangliosides were found to differentially stimulate HGF production by these cells. The ganglioside GD3 enhanced this release to the greatest extent and the stimulation was more marked in a glioblastoma cell line than in the two other anaplastic astrocytoma cell lines. These results suggest that both TGF-βs and gangliosides may act as indirect angiogenic factors by stimulating HGF secretion.


Journal of Clinical Neuroscience | 2013

Relationship between SATB1 expression and prognosis in astrocytoma

Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Jian-Hua Qiu; Zhi-An Zhu; Zhi-Qiang Li; Pu-Cha Jiang

Special AT-rich-sequence-binding protein 1 (SATB1), a new type of gene regulator, has been reported to be expressed in various human cancers and may be associated with malignancy. The aim of this study was to investigate the expression of SATB1 in astrocytoma and to determine its prognostic value for the overall survival of patients with astrocytoma. The expression of SATB1 protein and messenger RNA (mRNA) in human astrocytoma specimens was examined using immunohistochemistry and semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). The relationship between SATB1 expression and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was also investigated. Spearmans correlation coefficient was used to describe the association between SATB1 expression and the clinical parameters of astrocytoma patients. SATB1 protein and mRNA were expressed at significant levels in astrocytoma specimens. SATB1 expression was positively correlated with astrocytoma pathological grade but negatively correlated with the life span of astrocytoma patients. SATB1 expression was also significantly lower in astrocytoma specimens with MGMT promoter methylation than in those without MGMT promoter methylation. Our findings suggest that SATB1 may have an important role as a positive regulator of astrocytoma development and progression and that SATB1 might be a useful molecular marker for predicting the prognosis of patients with astrocytoma and could be a novel target for treating astrocytoma.


Molecular Biology Reports | 2009

Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1

Sheng-Hua Chu; Dong-Fu Feng; Yan-Bin Ma; Zhi-An Zhu; Hong Zhang; Jian-Hua Qiu


Molecular Medicine Reports | 2011

Effect of 5-Aza-2'-deoxycytidine on SLC22A18 in glioma U251 cells

Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Jian-Hua Qiu; Zhi-An Zhu


Oncology Reports | 2010

c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel

Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Jian-Hua Qiu; Zhi-An Zhu


Journal of Surgical Research | 2007

c-Met Antisense Oligodeoxynucleotides as a Novel Therapeutic Agent for Glioma: In Vitro and In Vivo Studies of Uptake, Effects, and Toxicity

Sheng-Hua Chu; Hong Zhang; Yan-Bin Ma; Dong-Fu Feng; Zhi-An Zhu; Xianhou Yuan; Zhiqiang Li

Collaboration


Dive into the Zhi-An Zhu's collaboration.

Top Co-Authors

Avatar

Dong-Fu Feng

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Hong Zhang

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Sheng-Hua Chu

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Yan-Bin Ma

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Jian-Hua Qiu

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Er-Tao Chen

Shanghai Jiao Tong University

View shared research outputs
Researchain Logo
Decentralizing Knowledge